New therapies for uveal melanoma target radiation toxicity, metastatic risk

Ongoing research for the treatment of uveal melanoma is providing hope that the future may bring new approaches for improving the safety of local therapy–along with modalities that will increase survival by reducing metastatic risk.

Optimal Treatment of Metastatic Melanoma at Progression

Panelists: Jeffrey S. Weber, MD, PhD, NYU Langone Medical Center; Robert H. I. Andtbacka, MD, CM, Huntsman Cancer Institute; Georgina Long, MD, PhD, Melanoma Institute of Australia at the University of Sydney; Michael A. Davies, MD, PhD, University of Texas MD Anderson Cancer Center; Jason J. Luke, MD, University of Chicago

Pembrolizumab Plus Reduced Ipilimumab Dose Active in Advanced Melanoma

The combination of standard-dose pembrolizumab with four reduced doses of ipilimumab followed by standard-dose pembrolizumab had a manageable safety profile and antitumor activity in patients with advanced melanoma, according to the results of the phase Ib KEYNOTE-029 study published in Lancet Oncology.

The Cancer Genes Needed for Immunotherapy Response

Immune checkpoint inhibitor antibodies are a relatively new class of cancer drugs that are now approved to treat patients with late-stage melanoma and those with certain lung, bladder, head and neck, kidney, and other types of late-stage cancers.

Cancer in the News

Feature Articles

Scientists Discover Dozens of New Genes that Create T-Cell Resistant Cancer

Source: New York University, August 2017 A team of scientists has uncovered dozens of novel genes involved in resistance to therapies that harness the immune system to fight cancer. The findings, which appear in the journal Nature, enhance our understanding of why some cancers are resistant to immunotherapy. “We cast a wide, deep net and […]

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Vitamin B may help prevent melanoma

Vitamin B3 therapy may help prevent melanoma in those at greatest risk of developing the deadly skin cancer.

Read the full story

Posted in Melanoma In The News, Information

Patient age associated with lymph node positivity in thin melanomas

Patient age was a factor in regional lymph node positivity in clinically localized melanomas 0.5 mm to 10 mm, according to recently published study results in JAMA Dermatology.

Read the full story

Posted in Melanoma In The News

Ipilimumab Approved by FDA for Pediatric Melanoma

Ipilimumab (Yervoy) has been approved by the FDA for the treatment of patients aged greater than or equal to 12 years with unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.

Read the full story

Posted in Melanoma In The News, FDA

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories